Finance

Professor Bill Trombetta takes a snapshot of the "Glamour 24" companies shaping the pharma industry this year and beyond

Bill Trombetta expands his annual guide to stellar performance with the "Heavenly 27."

The latest dealmaking trends: Early-stage is back in favor. There's more money to be made in being acquired than in going public. And license deals are putting more on the back end.

Lovenox still needs a defense strategy to hold share, but it requires less investment as a specialty product. Instead, Lovenox should throw cash over to Acomplia, the putative future star of the Sanofi-Aventis portfolio.